Contacts, documents and full notice history are available with a subscription.
Award Notice NONE 2 notices 1 document

Q301 - ClonoSEQ Measurable Residual Disease (MRD) Testing Services 36C25026Q0104

Solicitation 36C25026Q0104 Copied Notice ID e6cbe2cc166a4e9e90b2f5f9d5e93401 Copied VETERANS AFFAIRS, DEPARTMENT OF — 250-NETWORK CONTRACT OFFICE 10 (36C250)
SAM.gov
Posted
Dec 30, 2025
Deadline
No deadline
Set-aside
NONE
NAICS
621511
PSC
Q301

Summary

AI-generated · Nov 05, 2025

MRD testing services must be performed using the clonoSEQ Assay, a proprietary molecular test that is produced exclusively by Adaptive Biotechnologies, for use within VA Northeast Ohio Healthcare System’s PALMS. A contract will be pursued as a sole-source action under FAR 6.302-1, with Adaptive Biotechnologies identified as the only provider of clonoSEQ MRD testing in the United States; no competitive solicitation package is provided.

Although this notice indicates a sole-source intent, the agency will consider capability statements from any responsible source that can meet the requirement and demonstrate that competition would be advantageous. If you can meet the need, submit a capability statement to the designated contact by the stated deadline; responses are not paid for, and the government will decide, at its discretion, whether to pursue competition.

Notice of Intent to Sole-Source Requirement: The Department of Veterans Affairs, Network Contracting Office (NCO) 10, intends to negotiate a sole source contract under Simplified Acquisition Procedures and the authority of FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. The associated NAICS code for this is 621511, Size Standard is $41.5 Million. The Product Service Code (PSC) is Q301. The sole-source contract will be awarded to: ADAPTIVE BIOTECHNOLOGIES CORPORATION UEI: DMW5BNQ331K9 Description of requirements: The VA Northeast Ohio Healthcare System (VANEOHS), Pathology and Laboratory Medicine Service (PALMS), requires molecular minimal residual disease (MRD) testing services utilizing the clonoSEQ Assay provided exclusively by Adaptive Biotechnologies. The clonoSEQ Assay is a proprietary, patented molecular test developed and performed exclusively by Adaptive Biotechnologies. Adaptive Biotechnologies is the sole source provider of clonoSEQ MRD testing within the United States. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet this requirement. It is the Government's intention to solicit and negotiate with only this source. This notice of intent is not a request for competitive proposals. IAW FAR 5.207 all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. This is not a solicitation or request for offers. No solicitation package is available. Any response to this notice must show clear and convincing evidence that demonstrates the ability to comply with the requirement and that competition would be advantageous to the Government. The Government will not pay for information submitted. A determination not to compete based on responses to this notice is solely within the discretion of the Government. All responses to this intent to sole source must be emailed to Thomas Bellamy @ thomas.bellamy@va.gov by 3:00 p.m. EST November 12th, 2025.

From Special Notice posted on Nov 04, 2025

The Department of Veterans Affairs, Network Contracting Office 10, made an award for a one (1) year firm fixed price (FFP) contract with Adaptive Biotechnologies Corporation, 1165 Eastlake Ave. E, Seattle WA, 98109 to provide Clono-Seq Assay testing services for the Louis Stokes VA Medical Center, Pathology & Laboratory Services (PALMS), 10701 East BLVD., Cleveland, OH 44106. The point of contact is Thomas Bellamy, Contracting Officer, Network Contracting Office 10 - Thomas.Bellamy@va.gov.

From Award Notice posted on Dec 30, 2025

Notice history

2
  1. Special Notice Posted Nov 04, 2025 View
  2. Award Notice LATEST Posted Dec 30, 2025

Details

Solicitation number 36C25026Q0104
Notice ID e6cbe2cc166a4e9e90b2f5f9d5e93401
Award number 36C25026P0251
Notice type Award Notice
Product / Service (PSC) Q301
NAICS 621511
Set-aside No Set aside used
Place of performance Cleveland, Ohio
Archive date Jan 14, 2026

Award Information

Awardee
1
Total Awarded
$243,750.00
Award Date
Dec 30, 2025

Award Notices

Q301 - ClonoSEQ Measurable Residual Disease (MRD) Testing Services View Notice

Posted: Dec 30, 2025

The Department of Veterans Affairs, Network Contracting Office 10, made an award for a one (1) year firm fixed price (FFP) contract with Adaptive Biotechnologies Corporation, 1165 Eastlake Ave. E, Seattle WA, 98109 to provide Clono-Seq Assay testing services for the Louis Stokes VA Medical Center, P...

Awardees

Company Name UEI CAGE Code Location
ADAPTIVE BIOTECHNOLOGIES CORPORATION DMW5BNQ331K9 5SRQ2 Seattle, WA

Documents

1
View on SAM.gov

Contacts

primary
Thomas Bellamy

Email

Phone

Agency

VETERANS AFFAIRS, DEPARTMENT OF
VETERANS AFFAIRS, DEPARTMENT OF
250-NETWORK CONTRACT OFFICE 10 (36C250)

Place of Performance

Cleveland, Ohio 44106
USA

Dates

Posted Dec 30, 2025 7 months ago
Last Updated Aug 06, 2026 2 days ago
Awarded Dec 30, 2025 7 months ago